Sera Prognostics (SERA) Expected to Announce Quarterly Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect Sera Prognostics to post earnings of ($0.23) per share for the quarter.

Sera Prognostics Stock Up 1.9 %

Shares of NASDAQ SERA opened at $4.22 on Wednesday. The business's 50 day moving average price is $5.54 and its 200 day moving average price is $6.73. The firm has a market cap of $142.52 million, a P/E ratio of -4.26 and a beta of 0.89. Sera Prognostics has a 52 week low of $3.84 and a 52 week high of $12.36.

Insider Buying and Selling at Sera Prognostics

In other news, Director Joshua Phillips sold 12,163 shares of the company's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the sale, the director now owns 2 shares in the company, valued at $12.78. This represents a 99.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Jackson sold 7,912 shares of Sera Prognostics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $6.38, for a total value of $50,478.56. Following the transaction, the general counsel now owns 120,561 shares of the company's stock, valued at approximately $769,179.18. This represents a 6.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,877 shares of company stock worth $480,677. Company insiders own 15.80% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads